Dr Peter Vickerman BSC DPhil
- 15-17 Tavistock Place
- WC1H 9SH
- T: +44 2076127886
Peter Vickerman is the senior modeller for the Social and Mathematical Epidemiology Group and the Centre for Research on Drugs and Health Behaviour (Faculty of Public Health and Policy) in which he supervises five other post-doc modellers. He has been a senior lecturer since 2007, and is an honorary researcher at the University of Bristol. He has been modelling the transmission of HIV, STIs and blood bourne viruses for 12 years, and infectious diseases for 16 years.
Peter teaches Ph.D. and M.Sc students, has taught on numerous M.Sc. study units, including lecturing and leading seminars, and has been the course organiser for a decision modelling study unit for the last five years.
Peter has published over 70 articles in peer reviewed journals, reviews articles for 20 journals, is on the editorial board for a peer-reviewed journal, and contributes to six international advisory groups. Originally trained as a mathematician, with a D.Phil in mathematical epidemiology of Leishmaniasis, his research has focused on the use of mathematical modelling with detailed epidemiological, biological and behavioural data to help understand and explore the transmission of different infectious diseases and the impact and cost-effectiveness of prevention measures. Specific expertise focuses on modelling the transmission of HIV and other STIs amongst different risk groups and blood bourne viruses transmitted between injecting drug users. His research interests include modelling the joint transmission and interaction of different infections (e.g. sexual transmission of HIV and HSV-2 or the transmission of HIV and Hepatitis C amongst injecting drug users) in different settings and exploring how the stage and type of epidemic can affect the impact and cost-effectiveness of different interventions. Methodological areas of interest include: understanding the implications of behavioural and biological data uncertainty on model impact and cost-effectiveness projections and exploring different methods of handling these uncertainties, especially through the use of Bayesian methods; and trying to understand and accurately model how new interventions affect different aspects of an individual’s risk behaviour and the subsequent transmission of different infections. He has extensive experience of conducting collaborative research with organisations in Asia (India, Pakistan, Bangladesh), sub-Saharan Africa (South Africa, Tanzania, Benin), Eastern Europe (Ukraine, Belarus, Russia) and UK and is the PI on a number modelling projects with the MRC, Wellcome, Bill and Melinda Gates Foundation, World Bank and WHO. He is also the Co-PI on a number of large research initiatives in India and Africa.
- Economic evaluation
- Impact evaluation
- Substance abuse
- Mathematical modelling
Disease and Health Conditions
- Infectious disease
- Sexually transmitted disease
- Sexually transmitted infection
- Euro area
- Europe & Central Asia (developing only)
- North America
- South Asia
- Sub-Saharan Africa (all income levels)
- Burkina Faso
- Russian Federation
- South Africa
- United Kingdom
- United States
- Antiretroviral Therapy
- Central And Eastern Europe
- Chlamydia Trachomatis
- Combination prevention
- Cost Effectiveness Analysis
- Eastern Europe
- Effectiveness Evaluations
- Female sex work
- Former Soviet Union
- HIV Prevention
- HIV Self Testing
- HIV Treatment
- HIV prevention
- Handling uncertainty
- Hepatitis B
- Hepatitis C
- Injecting Drug Use
- Injecting Drug Users
- Males Who Have Sex With Males
- Microbicides and Pre-exposure prophylaxis (PreP)
- Model Calibration
- Modelling And Mapping Disease Distribution
- Sex Work
- Transactional sex
- cost effectiveness
- mathematical modeling
- structural drivers
- sub-saharan africa
Can antiviral therapy for Hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility.
Martin, N.K.; Vickerman, P.; Foster, G.R.; Hutchinson, S.J.; Goldberg, D.J.; Hickman, M.;
J Hepatol, 2011; 54(6):1137-44
Understanding the trends in HIV and hepatitis C prevalence amongst injecting drug users in different settings-Implications for intervention impact.
Vickerman, P. ; Martin, N.K. ; Hickman, M. ;
Drug Alcohol Depend, 2011;
Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed.
Degenhardt, L.; Mathers, B.; Vickerman, P.; Rhodes, T.; Latkin, C.; Hickman, M.;
Lancet, 2010; 376(9737):285-301
To what extent is the HIV epidemic in southern India driven by commercial sex? A modelling analysis.
Vickerman, P.; Foss, A.M.; Pickles, M.; Deering, K.; Verma, S.; Demers, E.; Lowndes, C.M.; Moses, S.; Alary, M.; Boily, M.C.;
AIDS, 2010; 24(16):2563-72
Modelling the transmission of HIV and HCV among injecting drug users in Rawalpindi, a low HCV prevalence setting in Pakistan.
Vickerman, P.; Platt, L.; Hawkes, S.;
Sex Transm Infect, 2009; 85 Suppl 2:ii23-30
Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis.
Vickerman, P.; Hickman, M.; May, M.; Kretzschmar, M.; Wiessing, L.;
Addiction, 2009; 105(2):311-8
Using Modeling to Explore the Degree to Which a Microbicide's Sexually Transmitted Infection Efficacy May Contribute to the HIV Effectiveness Measured in Phase 3 Microbicide Trials.
Vickerman, P.; Foss, A.; Watts, C.;
J Acquir Immune Defic Syndr, 2008; 48(4):460-7
Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study.
Vickerman, P.; Hickman, M.; Judd, A.;
Int J Epidemiol, 2007; 36(2):396-405
- → View all Dr Peter Vickerman's publications